Inhibitors of beta integrin-G protein alpha subunit binding interactions
View Patent ↗Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
1. A conjugate comprising a peptide and a heterologous moiety, wherein the peptide comprises an amino acid sequence
Phe-Xaa 1 -Xaa 2 Glu-Xaa 3 -Xaa 4
wherein Xaa 1 is Glu or Gin and Xaa 2 is Glu, Lys, Ser, or Ala,
wherein Xaa 3 is Lys, Arg, or Gln and Xaa 4 is Met, Leu, Ala, Ser, or Gln,
wherein the peptide is a 6-mer, 7-mer, or 8-mer.
2. The conjugate of claim 1 , wherein (i) Xaa 1 , is Glu and Xaa 2 is Glu, Lys, or Ala or (ii) Xaa 1 , is Gln and Xaa 2 is Ser.
3. The conjugate of claim 2 , wherein each of Xaa 1 and Xaa 2 is Glu.
4. The conjugate of claim 3 , wherein Xaa 3 is Arg and Xaa 4 is Ala.
5. The conjugate of claim 4 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87).
6. The conjugate of claim 1 , comprising a fatty acid.
7. The conjugate of claim 6 , comprising a C4-C30 fatty acid.
8. The conjugate of claim 6 , wherein the fatty acid is covalently attached to the N-terminus of the peptide.
9. The conjugate of claim 8 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87), wherein the Phe at position 1 is covalently attached to a fatty acid.
10. The conjugate of claim 9 , wherein the fatty acid is a C4-C30 fatty acid.
11. A micelle comprising the conjugate of claim 1 , wherein the peptide is covalently attached to a fatty acid, and the micelle comprises at least one lipid.
12. The micelle of claim 11 , wherein the lipid is covalently attached to a water soluble polymer.
13. A pharmaceutical composition comprising the conjugate of claim 1 , and a pharmaceutically acceptable carrier, diluent, or excipient.
14. A method of inhibiting thrombosis in a subject in need thereof comprising administering to the subject a conjugate of claim 1 , or a micelle comprising the conjugate, in an amount effective to inhibit thrombosis.
15. A method of treating a stroke or a heart attack in a subject in need thereof comprising administering to the subject a conjugate of claim 1 , or a micelle comprising the conjugate, in an amount effective to treat a stroke or a heart attack.